Odyssey Therapeutics Inc.
ODTX | NASDAQ
$19.33
-$0.21 (-1.07%)
Nov 2, 2026, 9:56 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Revenue | n/a | n/a |
Cost of Revenue | n/a | n/a |
Gross Profit | n/a | n/a |
Operating Income | -55.47M | -39.78M |
Interest Income | 2.83M | 1.71M |
Pretax Income | -52.8M | -38.2M |
Net Income | -52.79M | -38.26M |
Selling & General & Admin | 10.51M | 7.35M |
Research & Development | 36.23M | 32.32M |
Other Expenses | 8.73M | 109K |
Operating Expenses | 55.47M | 39.78M |
Interest Expense | 20K | 10K |
Selling & Marketing Expenses | n/a | n/a |
Cost & Expenses | 55.47M | 39.78M |
Income Tax Expense | -8K | 63K |
Shares Outstanding (Basic) | 30.28M | 47.17M |
Shares Outstanding (Diluted) | 30.28M | 47.17M |
EPS (Basic) | -1.74 | -0.81 |
EPS (Diluted) | -1.74 | -0.81 |
EBITDA | -51.73M | -37.02M |
EBIT | -52.78M | -38.19M |
Depreciation & Amortization | 1.04M | 1.17M |
Add to Watchlist
Select watchlists to add or remove ODTX